Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP & Chief Financial Officer | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 56,431 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Tax withholding · Disposed 3,343 · Balance 56,431 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
F2: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 22:04 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,343 | $237.72 | $794,697.96 |
DisclosureSEC source: 0002013156-26-000007 · edgardoc.xml · nonDerivative · entry 1 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,431 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,615 | $188.69 | $493,424.35 |
DisclosureSEC source: 0002013156-26-000004 · edgardoc.xml · nonDerivative · entry 1 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,608 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:22 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 11,857 | $0.00 | $0.00 |
DisclosureSEC source: 0002013156-26-000002 · edgardoc.xml · nonDerivative · entry 1 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,223 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: The Reporting Person acquired 166 ordinary shares on May 30, 2025 and 140 shares on November 28, 2025 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 23:51 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 1,149 | $138.95 | $159,653.55 |
DisclosureSEC source: 0001765581-25-000027 · edgardoc.xml · nonDerivative · entry 1 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,060 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 7,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000012 · edgardoc.xml · nonDerivative · entry 2 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,209 F3 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 15,407 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000012 · edgardoc.xml · nonDerivative · entry 1 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,505 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 12,000 | $119.65 | $1,435,800.00 |
DisclosureSEC source: 0001765581-24-000009 · edgardoc.xml · nonDerivative · entry 2 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,932 Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:28 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 15,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000009 · edgardoc.xml · nonDerivative · entry 1 Johnson Philip L · CIK 0002013156 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,932 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.